CoChat

The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome

Silverberg, Donald S. · 2011 · Heart Failure Reviews

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

Anemia is common in Congestive Heart Failure (CHF) and is associated with an increased mortality, morbidity and progressive renal failure. The most common causes of the anemia in CHF are (1) the associated Chronic Kidney Disease (CKD), which causes depression of erythropoietin (EPO) production in the kidney, and (2) excessive cytokine production in CHF, which can cause both depression of erythropoietin production in the kidney and depression of erythropoietin response in the bone marrow. The cytokines can also induce iron deficiency by increasing hepcidin production from the liver, which both reduces gastrointestinal iron absorption and reduces iron release from iron stores located in the macrophages and hepatocytes. It appears that iron deficiency is very common in CHF and is rarely recognized or treated. The iron deficiency can cause a thrombocytosis that might contribute to cardiovascular complications in both CHF and CKD and is reversible with iron treatment. Thus, attempts to control this anemia in CHF will have to take into consideration both the use of both Erythropoiesis Stimulating Agents (ESA) such as EPO and oral and, probably more importantly, intravenous (IV) iron. Many studies of anemia in CHF with ESA and oral or IV iron and even with IV iron without ESA have shown a positive effect on hospitalization, New York Heart Association functional class, cardiac and renal function, quality of life, exercise capacity and reduced Beta Natriuretic Peptide and have not demonstrated an increase in cardiovascular damage related to the therapy. However, adequately powered long-term placebo-controlled studies of ESA and of IV iron in CHF are still needed and are currently being carried out.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10741-010-9194-2

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 48

Metadata

Authors
Silverberg, D. S.
Affiliations
Tel Aviv Sourasky Medical Center (IL)
Corresponding author
Silverberg, Donald S.
Venue
Heart Failure Reviews
Published
2010-09-24
Volume
16
Issue
6
Pages
609-614
ISSN
  • 1382-4147 (ISSN-L)
  • 1573-7322
OpenAlex
W2091404630
Cited by
48
References
44
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 8
FWCI
3.01
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Heart Failure Reviews (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
cardiorenal anemia syndrome, congestive heart failure, anemia, erythropoiesis-stimulating agents, intravenous iron, erythropoietin, chronic kidney disease, iron deficiency, hepcidin, cytokines, thrombocytosis, renal function, cardiovascular outcomes
MeSH terms
Iron Deficiencies, Anemia, Bone Marrow, Cardiovascular System, Clinical Trials as Topic, Erythropoietin, Heart Failure, Hematinics, Humans, Infusions, Intravenous, Iron, Kidney, Syndrome, Trace Elements, Outcome Assessment, Health Care, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.